Pharmerging Markets 2016-2020

Pharmerging Markets 2016-2020

Category : Pharmaceuticals
Published On : November  2015
Pages : 104

------------ Or -------------
 Market outlook of the pharmerging markets

Technavios research analyst predicts the pharmerging markets to grow steadily at a CAGR of 13% during the forecast period. The increase in public and private healthcare insurance is the primary growth driver for this market. The governments of various pharmerging countries such as India have implemented several schemes that can be availed by patients to obtain free treatment for different diseases. Also, public and private multinational firms in collaboration with various insurance companies are providing healthcare coverage to their employees as a part of the employee welfare scheme, which is further leveraging people to seek treatment for the existing diseases.

The increase in healthcare spending by governments of pharmerging countries are expected to boost the market growth during the forecast period. Governments and pharmaceutical companies in these regions are making huge investments to improve accessibility to healthcare services, which is primarily driven by rising incomes, macroeconomic expansion, and government-supported policies and programs.

Segmentation and analysis of the pharmerging markets

Tier I countries (China)
	Tier II countries (Brazil, India, and Russia)
	Tier III countries (Poland, Argentina, Turkey, Mexico, Venezuela, Romania, Saudi Arabia, Colombia, Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria, and Ukraine)
The Tier I region (China) dominated the market during 2015, with a market share of 45%. An ageing population, increase in healthcare spending, and rise in market opportunities in suburban and rural areas are the main factors fueling the growth of the market in China.

Competitive landscape and key vendors

The pharmerging markets are highly fragmented due to the presence of numerous small and large vendors. Most of the international pharmaceutical companies are facing challenges such as price pressure, regulatory constraints, and competition from local and other international pharmaceutical companies in the pharmerging markets. The competitive environment in the market is expected to intensify with an increase in product extensions, technological innovations, and increase in mergers and acquisitions.

The leading vendors in the market are -

Other prominent vendors in the market include Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical, UCB, and Valeant Pharmaceuticals.

Key questions answered in the report include

What will the market size and the growth rate be in 2020
	What are the key factors driving the pharmerging markets
	What are the key market trends impacting the growth of the pharmerging markets
	What are the challenges to market growth
	Who are the key vendors in this market space
	What are the market opportunities and threats faced by the vendors in the pharmerging markets
	Trending factors influencing the market shares of Tier I, Tier II, and Tier III countries
	What are the key outcomes of the five forces analysis of the pharmerging markets
Technavio also offers customization on reports based on specific client requirement
Table of contents

PART 01: Executive summary

PART 02: Scope of the report

Market overview
PART 03: Market research methodology

Research methodology
Economic indicators
PART 04: Introduction

Key market highlights
PART 05: Global pharmaceuticals market

Market size and forecast
PART 06: Pharmerging markets

PART 07: Market landscape

Market size and forecast
Five forces analysis
PART 08: Market segmentation based on geography

PART 09: Market overview of Tier I countries

PART 10: Market overview of Tier II countries

PART 11: Market overview of Tier III countries

Market size and forecast
PART 12: Market drivers

Social and private health insurance
Increase in healthcare spending
High incidence of diseases
Impact of patent cliff on mature markets
PART 13: Impact of drivers

PART 14: Market challenges

Affordability and access
High competition
Partial regulatory policies
Price pressure
PART 15: Impact of drivers and challenges

PART 16: Market trends

Strategic alliances
Increase in generic sales
Mergers and acquisitions
Early drug launches in pharmerging markets
PART 17: Vendor landscape

Competitive scenario
Other prominent vendors
PART 18: Appendix

List of abbreviations
PART 19: Explore Technavio

Enquiry Before Buy